Skip to main content
OpenTrials
Completed

NCT Number: NCT01594112

Ability of Home Monitoring® to Detect and Manage the Inappropriate Diagnoses in Implantable Cardioverter Defibrillators.

The purpose of the THORN registry is to show the ability of Home-Monitoring® to early identify and manage the inappropriate diagnoses of ventricular arrhythmia in ICD patients (i.e. lead rupture, atrial arrhythmia, oversensing…) whatever the type of device (single, dual, or triple chamber).

The electromyograms (iEGMs) provided by Remote Patient Monitoring will help the physician to early detect inadequate arrhythmia detection (ID) that can be responsible for inappropriate therapies (IT), and to take preventive actions in order to reduce the burden of these inappropriate therapies.

THORN is an observational epidemiologic, prospective and multicenter registry. The primary objective is to measure the relative proportion of patients experiencing at least one inappropriate therapy during a fifteen months follow-up period. Moreover, THORN will assess the incidence, predictors, outcome and recurrence of inappropriate diagnoses in 1750 ICD patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

ICD Arrhythmias, Cardiac Atrial Fibrillation Cardiac Conduction System Disease Cardiovascular Diseases Death Death, Sudden Death, Sudden, Cardiac Heart Arrest Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Shock Sudden Cardiac Death Tachycardia Tachycardia, Ventricular Ventricular Fibrillation Ventricular Tachycardia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CH d'Aix en Provence, Aix-en-Provence, France

Loading trial locations.

About this study

Remote Patient Monitoring allows early detection of events that can generate inadequate detection of ventricular arrhythmia (i.e. lead rupture, atrial arrhythmia, oversensing….) and be responsible for inappropriate therapies. In such cases, it may be assumed that physicians can react earlier and take preventive actions, in order to reduce the risk or burden of inappropriate therapies.

The THORN registry has two purposes:

  • To determine retrospectively the relative proportion of patients experiencing at least one inappropriate therapy during 15-months of follow-up, in ICD patients equipped with Home Monitoring®. This part concern 1240 patients.
  • To evaluate prospectively the relationship between the detection of inappropriate diagnosis (with or without subsequent inappropriate therapy), the corrective action taken, and the recurrences of inappropriate diagnosis of the same origin/mechanism. This part concerns 510 patients.

BIOTRONIK Home Monitoring® by iEGM-Online® with Biotronik ICD devices (LUMAX) systematically stores any episode classified as ventricular tachycardia (VT) or ventricular fibrillation (VF) which is transmitted to the physician.

In the THORN study, in addition to the physicians' analysis, all electromyograms will be reviewed by an adjudication committee in order to classify them as appropriate or inappropriate diagnosis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject implanted with a single, dual, or triple chambers ICD within the last 3 months
  • Home Monitoring® activated and functional since hospital discharge
  • Patient willing and able to comply with the protocol and who has provided written informed consent about Home Monitoring®,
  • Patient whose medical situation is stable

Exclusion criteria

  • ICD replacements
  • New York Heart Association Function Class IV patients
  • Pregnant women or women who plan to become pregnant during the trial
  • Presence of any disease, other than patient's cardiac disease, associated with reduced likelihood of survival for the duration of the trial, e.g. cancer, uraemia (urea > 70mg/dl or creatinine >3mg/dl), liver failure, etc.
  • Age < 18 years
  • Patient unable to handle the Biotronik's transmitter correctly
  • Change of residence expected during the study
  • Insufficient global system for mobile communication (GSM) coverage at patient's home
  • Participation in another clinical study

Treatment and study plan

Primary outcomes

  1. Relative proportion of patients experiencing at least one inappropriate therapy (retrospective part) or more than one inappropriate therapy (prospective part)

    Time frame: 15 months

    Study of the relationship between the detection of ID, the corrective action taken and the recurrence of ID of the same mechanism.

Secondary outcomes

  1. Number of diagnoses per patient per year and relative proportion of patients with at least one diagnosis

    Time frame: 15 months

    The number of diagnoses per patient per year and the associated proportion of patients (with at least one diagnosis) will be measured. This will give the incidence rate of experiencing special classes of diagnoses over the 15-months follow-up period. The following subclasses will be assessed:

    Appropriate or not diagnoses, ID without therapy, therapies defined as shocks or antitachycardia pacing (ATP), shocks, inappropriate shocks, recurrence of ID and recurrence of inappropriate shocks.

    The prospective part will be compared to the retrospective part.

  2. Relative proportion of patients with a second day of ID

    Time frame: 15 months

    Knowing that the intervals between ID days cannot be predetermined (non normal distribution), medical reaction time anticipated with Home Monitoring® can reduce the number of patients with a second day of ID.

    The proportion of patients with more than one inappropriate diagnosis will be measured.

  3. Number of Asymptomatic Inappropriate therapy and Inappropriate therapy without diagnosis

    Time frame: 15 months

    Knowing that the main added value of Home Monitoring® relates on asymptomatic inappropriate therapies and inappropriate diagnoses without therapy (IDWT), the number of asymptomatic IT or IDWT patient per year and the associated proportion of patients (with at least one inappropriate diagnosis) will be measured.

  4. Time to the first ID

    Time frame: 15 months

    The time from the enrolment until the first EGM revealing the ID will be assessed.

  5. Medical reaction time to the ID

    Time frame: 15 months

    The time from the first ID to the follow-up visit during which a corrective action is taken is defined as the medical reaction time and will be assessed.

    In case of hospitalization without a follow-up visit (lead replacement for instance), the first day of hospitalization will be considered as the follow-up visit date.

    In current practice, the patients receiving shocks are advised to call their physicians in order to have their ICD interrogated. The analysis will distinguish the symptomatic IT and the asymptomatic ID (asymptomatic IT or IDWT).

  6. Number of days of recurrence within the medical reaction time

    Time frame: 15 months

    The number of days with at least one ID within the medical reaction time is defined as the number of days of recurrence and will be evaluated with the associated proportion of patients. The analysis will distinguish the symptomatic IT and the asymptomatic ID (asymptomatic IT or IDWT).

  7. Effectiveness of the corrective action and analysis according to the initial ID type

    Time frame: 15 months

    The proportion of patients with at least one inappropriate diagnosis recurrence (first day of recurrence) after the corrective action, and with the same ID mechanism as the original one, will be evaluated.

    A subgroup analysis depending on the ID mechanism will be performed, considering the inhomogeneous efficiency of the corrective action depending on the initial mechanism of the inappropriate diagnosis/therapy .

    The time from the follow-up visit during which the corrective action is taken until the next ID will be measured to assess the effectiveness of the corrective action.

  8. Classification of ID

    Time frame: 15 months

    The proportion of patient in the following classes of ID episodes will be evaluated:

    • Atrial fibrillation,
    • Other forms of supraventricular tachyarrhythmia
    • Sinus tachycardia
    • Abnormal sensing (T wave oversensing, interferences,…)
    • Other: the comparison is performed as an inter observer comparison between the Adjudication Board's and the physician's classification.

  9. Total number of hospitalizations/deaths related to ID and IT

    Time frame: 15 months

    Knowing that inappropriate therapies are among the heaviest ICD side-effects, the total number of hospitalizations and deaths related to ID or IT will be assessed.

  10. Risk of all-cause mortality

    Time frame: 15 months

    The risk of death associated with inappropriate therapy only, with the inappropriate shocks only, with any shocks, without any therapy, without any shocks will be evaluated.

Sponsors and collaborators

Lead sponsor

Biotronik SE & Co. KG

Industry

Registry information

Official study title

Inappropriate Therapies and Home Monitoring® in Implantable Cardioverter Defibrillators (ICD)

Acronym: THORN

Important dates

Study start
2012
Primary completion
2013
Study completion
2015
First posted
May 8, 2012
Registry last updated
Mar 17, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.